Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001600620-26-000020
Filing Date
2026-03-03
Accepted
2026-03-03 16:13:25
Documents
1
Period of Report
2026-02-27

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1772572400.html 4  
1 FORM 4 wk-form4_1772572400.xml 4 5652
  Complete submission text file 0001600620-26-000020.txt   7019
Mailing Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6
Business Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 250-744-2487
Aurinia Pharmaceuticals Inc. (Issuer) CIK: 0001600620 (see all company filings)

EIN.: 981231763 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address #140-14315 118 AVE NW EDMONTON A0 T5L 4S6
Business Address
Keenan Greg (Reporting) CIK: 0002044006 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-36421 | Film No.: 26714252